Novartis
NEWS
BioSpace scanned the WARN (Worker Adjustment and Retraining Notification) notices across the country and compiled a small list of recent layoffs across the industry.
It was another busy week for clinical trials. Here’s a look.
In a Phase III trial, Cosentyx showed a significant and clinically meaningful reduction in disease activity for patients versus placebo.
Swiss pharma giant Novartis has partnered with tech giant Microsoft and launched its Novartis AI innovation lab as a means to leverage data and artificial intelligence to transform drug discovery and development.
In a 56-page response to the investigation from the U.S. Food and Drug Administration, Novartis said the Kaspar brothers personally manipulated or instructed others to alter some of the preclinical data that ultimately led to the approval of the $2.1 million priced SMA therapy.
According to the second biennial 2019 Life Sciences Ideal Employer Report by BioSpace, the top three most important attributes cited by life sciences professionals around the world are the opportunity to do interesting and meaningful work, a competitive salary and health benefits.
Last week was an unusually busy week for clinical trial news, with numerous companies presenting results at conferences. Here’s a look at the top stories.
AveXis presented new interim data from the Phase III SPR1NT trial of Zolgensma (onasemnogene abeparvovec-xioi) in spinal muscular atrophy (SMA) Type 1.
50 million people worldwide live with symptomatic Alzheimer’s, which has no cure. In honor of September 21st being World Alzheimer’s Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
JOBS
IN THE PRESS